Table 3.
Unadjusted healthcare costs measured per patient per month among patients with metastatic non-small-cell lung cancer epidermal growth factor receptor activating mutation with and without disease progression within 12 months after first-line initiation on an epidermal growth factor receptor tyrosine kinase inhibitor.
| PPPM healthcare costs; Mean (SD) | No disease progression in the first 12 months (n = 127) | Disease progression in the first 12 months (n = 101) | Disease progression in months 0–6 (n = 46) | Disease progression in months 7–12 (n = 55) |
|---|---|---|---|---|
| Inpatient | $808 ($2872) | $5533 ($14,795)§ | $7508 ($19,080)§ | $3882 ($9792)§ |
| Outpatient medical† | $3923 ($4299) | $6633 ($7004)§ | $7374 ($6518)§ | $6,013 ($7387)§ |
| Emergency room | $56 ($160) | $362 ($1146)§ | $485 ($1548)§ | $259 ($642)§ |
| Office administered antineoplastics | $2 (22) | $1106 ($2482)§ | $1205 ($2847)§ | $1024 ($2152)§ |
| Infusion costs (i.e., administration costs for antineoplastics)† | $0.3 ($3) | $60 ($153)§ | $75 ($193)§ | $48 ($108)§ |
| Office visits | $310 ($253) | $265 ($177) | $254 ($196) | $273 ($161) |
| Radiology services | $1689 ($2658) | $2498 ($5240) | $2838 ($3966)§ | $2213 ($6128) |
| Laboratory services | $238 ($378) | $324 ($564) | $383 ($736) | $274 ($365) |
| Other outpatient services‡ | $1630 ($1936) | $3185 ($3488)§ | $3414 ($3796)§ | $2993 ($3231)§ |
| Total medical (inpatient + outpatient services + outpatient treatment) | $4731 ($5333) | $12,167 ($16,944)§ | $14,883 ($20,152)§ | $9895 ($13,480)§ |
| Outpatient pharmacy | $12,639 ($5077) | $8017 ($4593)§ | $7990 ($5233)§ | $8040 ($4030)§ |
| Antineoplastic pharmacy prescription costs | $12,319 ($5,080) | $7652 ($4522)§ | $7718 ($5214)§ | $7597 ($3899)§ |
| Other pharmacy prescription costs | $319 ($433) | $365 ($778) | $271 ($373) | $443 ($996) |
| Total (medical + pharmacy) | $17,370 ($8285) | $20,184 ($18,068) | $22,872 ($21,848)§ | $17,936 ($13,982) |
| Total (excluding all antineoplastic treatment costs both medical and pharmacy) | $5049 ($5401) | $11,425 ($16,810)§ | $13,949 ($20,004)§ | $9314 ($13,410)§ |
†
Procedure codes for antineoplastic administration.
‡
Inclusive of all other outpatient services not reported out individually.
§
Comparison p ≤ 0.05 versus no disease progression.
EGFRm: Epidermal growth factor receptor activating mutation; mNSCLC: Metastatic non-small-cell lung cancer; PPPM: Per patient per month; SD: Standard deviation; TKI: Tyrosine kinase inhibitor.